Comparative Pharmacology
Head-to-head clinical analysis: ALBENDAZOLE versus VERMIDOL.
Head-to-head clinical analysis: ALBENDAZOLE versus VERMIDOL.
ALBENDAZOLE vs VERMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
VERMIDOL is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis and attenuating pain, inflammation, and fever.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
200 mg orally twice daily for 3 days; maximum 400 mg per day.
None Documented
None Documented
Clinical Note
moderateAlbendazole + Digoxin
"Albendazole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlbendazole + Digitoxin
"Albendazole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlbendazole + Deslanoside
"Albendazole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAlbendazole + Acetyldigitoxin
"Albendazole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h) and elderly.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Renal: ~60-70% as unchanged drug; biliary/fecal: ~20-30%; minor metabolism via hepatic CYP3A4.
Category D/X
Category C
Anthelmintic
Anthelmintic